Andrey Ignatenko

Associate

Andrey Ignatenko advises on mergers and acquisitions, corporate, regulatory, and compliance matters. He has worked with clients in various industries, including automotive, media, and pharmaceutical. Prior to joining Morgan Lewis, Andrey served as a paralegal in the corporate practice of another international law firm resident in Moscow. He is fluent in Russian and English.

Selected Representations

Advised a leading global healthcare company, through its Belgian subsidiary, on the sale (including a long-term manufacturing and supply agreement for the Russian market) of a Russian distribution company, which sells a wide range of traditional and homeopathic over-the-counter products, to a global pharmaceutical company focused on developing, manufacturing, and selling generic, brand, over-the-counter, and biosimilar products
Counseled a European manufacturer of optical medical devices on obtaining necessary regulatory approvals for the distribution of its products in Russia, including approvals for clinical trials
Advised a global biopharmaceutical company on regulatory pathways for the approval of biosimilar products
Advised a global biopharmaceutical company—which develops and delivers life-transforming therapies for patients with rare, life-threatening diseases—on regulatory matters, including the addition of some of the company’s drugs on the Russian vital and essential drugs list
Counseled a global biopharmaceutical company on localization of its product manufacturing
Advised the mass media division of one of the world’s largest media conglomerates focused primarily on cinema and cable television on a joint venture (which broadcast and distributed more than 10 pay television channels in Russia) with a Russian company related to a prominent Russian business group
Advised one of the largest US diversified media and information groups on the restructuring of its Russian publishing joint venture, and the negotiation of a joint venture with a Russian partner, to comply with a Russian law imposing a 20% cap on non-Russian (foreign) investments in Russian media companies. The business published popular magazines in the Russian market and neighboring countries
Counseled a leading global financial services firm on the sale of a minority stake in a large Russian bank to principals of one of Russia’s largest private banks
Advised a leading provider of global mobile satellite services on the sale of its Russian subsidiary
Advised a global healthcare company manufacturing branded generic pharmaceuticals, medical devices, and nutrition products on anticounterfeiting issues in Russia and the strategic development of a trademark portfolio in Russia and the CIS
Advised a large US company on a joint venture with the Kazakhstan national railway company and a Russian partner to produce diesel engines in Kazakhstan
Advised a global pharmaceutical company specializing in brain diseases on a master license and distribution agreement with a Russian distributor, including counseling on marketing campaigns
Advised a global biopharmaceutical company focused on specialist therapeutic areas of oncology, neurodegenerative diseases, fertility, endocrinology, cardiometabolic care, and general medicine products on a distribution and cooperation agreement with a Russian distributor
Advised an international television network on arrangements to cover the XXII Olympic Winter Games in Sochi
Advised an Italian engineering company on the acquisition of a stake in a Russian state-owned engineering company
Advised non-Russian and Russian clients on health and pharmaceutical sector regulatory issues, including the registration and import of medicines and medical devices into Russia
Counseled manufacturers of orphan drugs on their business activities in Russia, including regulatory compliance and relations with patient groups
Advised clients on compliance with rules for pharmaceutical marketing and distribution in Russia involving samples, company visits, gifts, and entertainment